Get started
Author

Irene Otero

Observed names: I. Otero, Lasheras Otero, Irene
ORCID: 0000-0002-6806-3716
Observed ORCID: 0000-0002-6806-3716
OpenAlex ID: A5001235160
CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2018 · Carolina Rubio, Mónica Martínez-Fernández, et al. · Clinical Cancer Research · 64
Exosomes: Definition, Role in Tumor Development and Clinical Implications
2018 · Alberto Carretero-González, Irene Otero, et al. · Cancer Microenvironment · 43
Urothelial cancer proteomics provides both prognostic and functional information
2017 · Guillermo de Velasco, Lucia Trilla-Fuertes, et al. · Scientific Reports · 30
PDF
Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials
2019 · Alberto Carretero-González, David Lora, et al. · Oncotarget · 17
PDF
Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.
2021 · Alberto Carretero-González, Irene Otero, et al. · OncoImmunology · 15
PDF
IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in advanced soft tissue and bone sarcomas: Results of the phase II- soft-tissue sarcoma cohort
2019 · J Martin Broto, N. Hindi, et al. · Annals of Oncology · 13
IMMUNOSARC: A collaborative Spanish (GEIS) and Italian (ISG) Sarcoma Groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—Results of the phase I part.
2018 · Javier Martin Broto, Nadia Hindi, et al. · Journal of Clinical Oncology · 12
Nivolumab induced immune mediated transverse myelitis in a patient with metastatic melanoma: The broad clinical spectrum of immune mediated neurologic disorders
2021 · Mateo Bover, Irene Otero, et al. · Current Problems in Cancer Case Reports · 4
RB-independent activity of Cdk4/6 in bladder cancer.
2016 · Daniel E. Castellano, Carolina Rubio, et al. · Journal of Clinical Oncology · 4
Abstract 4854: A translational multiplexed hypothesis generating study on circulating cytokines in patients with cancer cachexia
2019 · Mª Teresa Agullo-Ortuño, Virginia Pardo-Marques, et al. · Cancer Research · 2
Split-Dose Cisplatin Plus Atezolizumab for Patients With Urothelial Carcinoma Who Are Considered Ineligible for Full Doses of Cisplatin (SOGUG-AUREA)
2025 · Guillermo de Velasco, Iciar García-Carbonero, et al. · JCO oncology advances. · 1
8P Cdk4/6 inhibitor activity in metastatic bladder cancer cell lines is independently of RB1 status
2016 · D. Castellano, C. Rubio, et al. · Annals of Oncology · 1
PDF
Regulación metabólica de anoikis e implicaciones en la metástasis del melanoma
2023 · Lasheras Otero, Irene · Academica-e (Universidad Pública de Navarra)
Supplementary Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Supplementary Table 5 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Supplementary Table 4 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Supplementary Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
PDF
Supplementary Table 4 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Supplementary Table 6 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Supplementary Table 5 from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Data from CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status
2023 · Carolina Rubio, Mónica Martínez-Fernández, et al.
Abstract 4854: A translational multiplexed hypothesis generating study on circulating cytokines in patients with cancer cachexia
2019 · Mª Teresa Agullo-Ortuño, Virginia Pardo-Marques, et al. · Clinical Research (Excluding Clinical Trials)
Metabolomics in cancer cachexia
2017 · J.A. Lopez-Martin, M. Cala, et al. · Annals of Oncology
Abstract PR01: Therapeutic targeting of cdk4 in bladder cancer
2016 · Carolina Rubio, Fernando López-Calderón, et al. · Molecular Cancer Research
Works count: 28
Citation count: 206
H-index: 7
I10-index: 7
Year
Topic
Type